6/25/2021 | PV | Synchronoss issues B. Riley $75 million series B preferred stock
|
6/25/2021 | HYPF | New Issue: Synchronoss prices $125 million 8.375% $25-par five-year notes
|
6/24/2021 | PF | Synchronoss plans $120 million $25-par five-year senior notes
|
9/17/2018 | CV | Market Commentary: Splunk on tap; trading volume light; DocuSign notes in focus; Tesla better; Synchronoss active
|
11/15/2017 | BK | Synchronoss Technologies repays in full, terminates credit agreement
|
7/3/2017 | BK | Synchronoss lenders waive default from missed deadline for financials
|
6/23/2017 | CV | Market Commentary: Synchronoss convertibles firm on buyout interest; Red Hat moves with stock; PROS paper eyed
|
6/23/2017 | CV | Market Commentary: Morning Commentary: Synchronoss convertibles firm on buyout interest; Red Hat moves with stock
|
6/22/2017 | BK | Synchronoss seeks amendment to extend financial delivery deadline
|
5/1/2017 | CV | Market Commentary: Blackstone Mortgage in market; recent deals in play; BroadSoft hit post-earnings
|
5/1/2017 | CV | Market Commentary: Morning Commentary: Synchronoss active; Neurocrine holds in; Blackstone Mortgage in market
|
4/28/2017 | BKCV | S&P puts Synchronoss on watch
|
4/27/2017 | BKCV | Moody’s might drop Synchronoss
|
4/27/2017 | CV | Market Commentary: New convertibles from Flexion, Neurocrine jump over par post-pricing; Synchronoss suffers
|
1/19/2017 | BK | Market Commentary: AmWINS, Optiv, LANDesk, NRG, Travel Leaders, Alliant, KIK Custom, Gemini break for trading
|
1/13/2017 | CLHY | Market Commentary: Synchronoss, Dynegy, Travelport, Petco, Berry, 1-800, Delos, Summit, Affinity, US LBM break
|
1/13/2017 | BK | Market Commentary: Synchronoss, Dynegy, Travelport, Petco, Berry, 1-800, Delos, Summit, Affinity, US LBM break
|
1/12/2017 | CLHY | Market Commentary: TeamHealth, Ellucian break; Synchronoss, Zayo, Dynegy, US LBM, 1-800 Contacts tweak deals
|
1/12/2017 | BK | Market Commentary: TeamHealth, Ellucian break; Synchronoss, Zayo, Dynegy, US LBM, 1-800 Contacts tweak deals
|
1/12/2017 | BK | Synchronoss cuts spread on $900 million term B to Libor plus 275 bps
|
1/10/2017 | CLHY | Market Commentary: Ascena dips with sales results; Valeant up on asset sale plans; Synchronoss revises deadline
|
1/10/2017 | BK | Market Commentary: Ascena dips with sales results; Valeant up on asset sale plans; Synchronoss revises deadline
|
1/5/2017 | CLHY | Market Commentary: Solera trades lower with Autodata acquisition news; primary sees multiple deal launches
|
1/5/2017 | BK | Market Commentary: Solera trades lower with Autodata acquisition news; primary sees multiple deal launches
|
1/5/2017 | BKCV | Moody’s: Synchronoss CFR B1, facility Ba3
|
1/5/2017 | BK | Synchronoss talks $900 million term loan B at Libor plus 300-325 bps
|
1/5/2017 | BKCV | S&P rates Synchronoss loan BB-, convertibles B
|
1/3/2017 | CLHY | Market Commentary: LANDesk reacts to buyout news; First American, Intermedia free to trade following updates
|
1/3/2017 | BK | Market Commentary: LANDesk reacts to buyout news; First American, Intermedia free to trade following updates
|
1/3/2017 | BK | Synchronoss to launch $1.15 billion credit facility on Thursday
|
12/6/2016 | BK | Synchronoss plans $900 million term loan for Intralinks purchase
|
7/11/2016 | BK | Synchronoss Technologies gets five-year $250 million restated revolver
|
3/12/2015 | PP | Market Commentary: Intel trades mixed after guidance cut; Microchip slips on hedge; Synchronoss adds outright
|
3/12/2015 | CV | Market Commentary: Intel trades mixed after guidance cut; Microchip slips on hedge; Synchronoss adds outright
|
8/12/2014 | CV | Synchronoss greenshoe brings 0.75% convertibles to $230 million
|
8/8/2014 | PP | Market Commentary: Jazz Pharmaceuticals deal prices, trades actively; Synchronoss new issue slips slightly
|
8/8/2014 | CV | Market Commentary: Jazz Pharmaceuticals deal prices, trades actively; Synchronoss new issue slips slightly
|
8/8/2014 | CV | Market Commentary: Morning Commentary: Jazz Pharmaceuticals prices new deal, trades actively; Synchronoss steady
|
8/7/2014 | PP | Market Commentary: Synchronoss’ 0.75% notes dominate, trade above par; Empire State prices; MolyCorp mixed
|
8/7/2014 | CV | Market Commentary: Synchronoss’ 0.75% notes dominate, trade above par; Empire State prices; MolyCorp mixed
|
8/7/2014 | CV | Market Commentary: Morning Commentary: Synchronoss’ new 0.75% notes dominate, trade above par; MolyCorp gains
|
8/7/2014 | CV | New Issue: Synchronoss sells $200 million five-year convertible notes at 0.75%, up 37.5%
|
8/5/2014 | CV | Synchronoss Technologies offers $200 million five-year convertibles at 0.75%-1.25%, up 32.5%-37.5%
|
10/2/2013 | BK | Synchronoss secures five-year $100 million revolver via JPMorgan
|
2/1/2010 | CVHY | Synchronoss files $150 million shelf covering stock, debt, preferreds
|